Rolf Andrew Ramelmeier - Feb 25, 2022 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
EVP, Technical Operations
Signature
Rolf Andrew Ramelmeier, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
SGMO
Transactions as of
Feb 25, 2022
Transactions value $
-$73,089
Form type
4
Date filed
3/1/2022, 04:19 PM
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Tax liability -$73.1K -12.4K -12.29% $5.90 88.4K Feb 25, 2022 Direct F1, F2, F3
transaction SGMO Common Stock Award $0 +54K +61.07% $0.00 142K Feb 25, 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMO Stock Option (Right to Buy) Award $0 +146K $0.00 146K Feb 25, 2022 Common Stock 146K $5.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").
F2 Includes: (a) 2,727 shares resulting from the February 25, 2022 final vesting installment of the Reporting Person's February 25, 2019 RSU grant, (b) 11,993 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 18,337 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, and (c) 8,722 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 26,668 shares subject to such RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 25, 2023 and 2024, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F3 Includes 2,000 shares acquired on April 30, 2021 and 346 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan and 272 shares acquired on May 8, 2021 under the Issuer's 2020 Employee Stock Purchase Plan.
F4 Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F5 One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.